1 July 2005 Optical molecular imaging of lymph nodes using a targeted vascular contrast agent
Author Affiliations +
Abstract
We develop a highly specific antibody-dye conjugate for optical imaging of peripheral lymph nodes. The contrast agent consists of the monoclonal antibody recognizing endothelial ligands for the lymphocyte homing receptor L-selectin, MECA-79, and a near-infrared (near-IR) fluorescent indotricarbocyanine dye. The targeting and biodistribution behavior of MECA-79 is studied after radio-iodination and intravenous injection into mice demonstrating specific uptake in lymph nodes and accumulation in high endothelial venules (HEV). After conjugation of MECA-79 with indotricarbocyanine dye, the fluorescence imaging properties of the MECA-79 dye conjugate are examined by intravenous injection in nude mice and laser-induced fluorescence whole-body imaging in vivo. The MECA-79 antibody-dye conjugate accumulates in peripheral lymph nodes, whereas an isotype antibody-dye conjugate does not. Specific lymph node near-IR fluorescent signals become detectable within minutes after injection, and stable imaging persists for more than 24 h. The results demonstrate that vascular targeting of endothelial expression of glyocproteins is feasible to visualize the accumulation of near-IR fluorescent MECA-79 in lymph nodes, making this technology potentially useful to characterize processes of inflammation.
© (2005) Society of Photo-Optical Instrumentation Engineers (SPIE)
Kai Licha, Kai Licha, N. Debus, N. Debus, S. Emig-Vollmer, S. Emig-Vollmer, B. Hofmann, B. Hofmann, M. Hasbach, M. Hasbach, D. Stibenz, D. Stibenz, S. Sydow, S. Sydow, Michael Schirner, Michael Schirner, Bernd Ebert, Bernd Ebert, Diethard Petzelt, Diethard Petzelt, C. Bührer, C. Bührer, W. Semmler, W. Semmler, R. Tauber, R. Tauber, } "Optical molecular imaging of lymph nodes using a targeted vascular contrast agent," Journal of Biomedical Optics 10(4), 041205 (1 July 2005). https://doi.org/10.1117/1.2007967 . Submission:
JOURNAL ARTICLE
6 PAGES


SHARE
Back to Top